Overview of Soline

Property	Description
Active Ingredient	Solifenacin succinate
Form	Film-coated tablets
Pharmacological Class	Muscarinic Receptor Antagonist
Common Use	Improving bladder control and capacity
Origin	Synthetic (Quinuclidine derivative)

Soline is a prescription-only medicine that is a single-ingredient product, delivered as an oral formulation in the form of film-coated tablets. The medicine's core component is the active ingredient, Solifenacin succinate.

The compound Solifenacin is chemically a synthetic substance, characterized as a quinuclidine derivative. It is produced through chemical synthesis, ensuring its consistent and targeted action. The film-coated tablet form is designed for systemic action following oral administration, ensuring the active ingredient is efficiently absorbed into the bloodstream to reach the target site. This preparation contains Solifenacin succinate and solid pharmaceutical excipients.

Solifenacin is classified as a competitive muscarinic receptor antagonist, placing it within the broader category of anticholinergic agents. This pharmacological identification specifies that the drug interferes with the signaling of muscarinic receptors in the body, which are responsible for muscle function.

The functional purpose of Soline is rooted in its highly selective action of inhibiting the signals that trigger involuntary contractions of the bladder’s smooth muscle. This selective targeting of the M3 receptor promotes bladder smooth muscle relaxation. By stabilizing the bladder and inhibiting frequent, unprompted bladder contraction, Soline is primarily utilized for improving control and reducing the urgency associated with involuntary bladder activity.

What side effects are possible with Soline?

Possible Side Effects and Safety Information

The safety profile of Soline (solifenacin succinate) is officially documented by government regulatory authorities, establishing the range and frequency of possible adverse reactions. The most frequent reactions are generally consistent with the drug’s pharmacological class as a muscarinic receptor antagonist.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on their incidence in clinical use and post-marketing surveillance:

Very Common: The most frequently reported effect is dry mouth (xerostomia).
Common: Reactions in this tier include constipation, blurred vision, nausea, and dyspepsia (indigestion). These common effects, particularly dry mouth and constipation, may be more pronounced at the beginning of treatment.
Uncommon: This category lists effects such as urinary tract infection, somnolence, fatigue, and dry eye.
Rare: Documented rare reactions include urinary retention, dizziness, and rash.

Organ System Involvement and Serious Reactions

The officially listed effects are primarily observed in the Gastrointestinal (e.g., abdominal pain), Eye, and Nervous Systems. In post-marketing experience, rare but serious adverse reactions have been documented:

Urinary Retention remains a rare, but clinically important, documented safety concern.
Hypersensitivity reactions, including angioedema (swelling of the face, tongue, or pharynx), have been reported.
Cardiac conduction abnormalities, such as QT prolongation and Torsade de Pointes, have also been reported in post-marketing data.

Population-Specific Safety Notes

The regulatory profile specifies safety limitations for certain populations. The use of Soline is generally not recommended or requires special consideration in individuals with severe hepatic impairment and severe renal impairment, due to the potential for increased drug exposure. Additionally, caution is officially advised in patients with clinically significant Bladder outlet obstruction and when the medicine is co-administered with potent CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that an overdose of Soline (solifenacin succinate) can potentially result in severe anticholinergic effects.

Documented Overdose Manifestations

Symptoms and clinical signs listed in regulatory labeling include pronounced central nervous system (CNS) effects such as mental status changes, decreased level of consciousness, confusion, and hallucinations. Physical manifestations observed in high-exposure cases include fixed and dilated pupils, tremors, and difficulty walking (failure of heel-to-toe exam).

Serious Outcomes and Emergency Action

Overdose carries a risk of life-threatening events, including seizure or collapse. Furthermore, the regulatory safety profile notes the potential for QT prolongation and Torsade de Pointes.

Regulatory documents mandate seeking immediate medical attention for any suspected overdose. Emergency services must be called immediately if the affected person has trouble breathing or can't be awakened.

Official Management Procedures

Management procedures described in regulatory labeling include gastric lavage and the provision of appropriate supportive measures to address the severe antimuscarinic effects. The treatment is primarily symptomatic and supportive, managed accordingly to the specific manifestations presented.

Therapeutic Uses of Soline

Soline (solifenacin succinate) is primarily used for the symptomatic management of chronic bladder conditions and is commonly used in situations involving certain distressing symptoms that interfere with daily functioning. Its use is applied across domains where additional symptomatic support is needed to address functional stability. The medication is relevant for easing challenging symptoms associated with Overactive Bladder Syndrome (OAB) and Neurogenic Detrusor Overactivity (NDO).

Managing Core Bladder Symptoms

Soline is applied in clinical contexts relevant for conditions characterized by periods of heightened symptoms, including sudden, compelling urinary urgency, high urinary frequency throughout the day, night-time waking (nocturia), and episodes of urge urinary incontinence. This medication generally helps to provide support to stabilize bladder function, which contributes to easing the overall symptom load when symptoms create noticeable physiological strain. The primary therapeutic focus is on managing storage symptoms and may assist in addressing functional bladder capacity.

Benefit and Patient Relevance

Soline is commonly used across the adult population for chronic OAB and in pediatric patients aged 2 years and older for OAB symptoms associated with conditions where functional stability becomes affected. It is also considered relevant for men experiencing storage-related Lower Urinary Tract Symptoms (LUTS). The symptomatic relief offered assists with maintaining functional stability and may help patients cope more steadily with managing the frequency of leakage episodes, supporting them during difficult episodes by easing distress.

Quick Fact: Supportive Management for Urinary Urgency and Frequency

Regulatory References

NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Soline — Official Regulatory Information

Soline eligibility is defined by official regulatory documents based on patient age, organ function, and pre-existing medical conditions. The tablet formulation is authorized for use in adults (age 18 and over). Use of the tablet is generally not established in patients under 18 years, though the oral suspension formulation is authorized for pediatric patients aged 2 years and older with Neurogenic Detrusor Overactivity.

Contraindications

Soline is contraindicated (must not be used) in patients with severe, high-risk conditions. These absolute prohibitions include known hypersensitivity to the drug, urinary retention, gastric retention, toxic megacolon, and uncontrolled narrow-angle glaucoma.

Restrictions

Use is restricted in patients with reduced organ function. Patients with severe renal impairment (CrCl le 30 mL/min) or moderate hepatic impairment (Child-Pugh B) must have their dose limited to 5 mg once daily. The medicine is not recommended for patients with severe hepatic impairment (Child-Pugh C). Use during pregnancy and lactation is generally not recommended due to limited safety data.

What should I know about interactions with other medicines?

Soline's interaction profile is primarily defined by its metabolism through the CYP3A4 enzyme system and its own pharmacological activity as an anticholinergic agent.

Documented Pharmacokinetic Interactions

Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir, Nelfinavir) is documented to result in a significant increase in Soline exposure (AUC). Conversely, CYP3A4 inducers (e.g., Rifampicin, Phenytoin, Carbamazepine) may decrease Soline plasma concentrations.

Interaction Type	Affected Products (Examples)
Pharmacokinetic uparrow Exposure	Potent CYP3A4 Inhibitors
Pharmacodynamic (Additive)	Other Anticholinergic Agents

Pharmacodynamic and Restricted Combinations

Concurrent use with other anticholinergic agents carries the risk of additive therapeutic and undesirable effects. Similarly, the effects of drugs that stimulate GI motility, such as Metoclopramide or Cisapride, may be reduced by Soline. An interval of approximately one week should be allowed after stopping Soline before commencing other anticholinergic therapy.

Co-administration with a potent CYP3A4 inhibitor is contra-indicated in patients who also have concurrent Severe Renal Impairment ( CLcr < 30 mL/ min) or Moderate Hepatic Impairment (Child-Pugh B). The film-coated tablets can be taken with or without food.

Mechanism of Action

Competitive Blockade of Muscarinic M3 Receptors

Soline's active ingredient, Solifenacin, acts as a competitive antagonist primarily targeting the Muscarinic M3 receptors located on the detrusor smooth muscle. By occupying these receptor sites, Solifenacin inhibits the binding of the excitatory neurotransmitter, Acetylcholine (ACh), thereby interfering with the initiation of the contraction signal. This targeted interaction contributes to the functional stabilization of the smooth muscle against involuntary excitatory input.

Inhibition of the Ca^2+ Contraction Cascade

The molecular blockade of the M3 receptor halts the subsequent intracellular signal transduction pathway. This interference prevents the necessary release of calcium ions ( Ca^2+) within the smooth muscle cells, which are essential for forming the molecular bridges required for muscle fiber shortening. This action directly suppresses the smooth muscle contraction cascade, promoting a state of detrusor muscle relaxation.

Detrusor Muscle Relaxation and Functional Storage Volume

The resulting inhibition of the contraction cascade leads to a state of sustained detrusor muscle relaxation. The reduction in excitatory signaling alters the threshold for involuntary smooth muscle activity, which results in an adjustment in the bladder's ability to achieve a greater functional storage volume. This physiological consequence is achieved through the continuous suppression of the parasympathetic contraction signal.

Dosage and Administration Information

Soline (solifenacin succinate) is administered orally and is available as film-coated tablets (5 mg and 10 mg) for adults and an oral suspension for pediatric patients. Its use follows a clear, label-based protocol designed for consistent systemic delivery.

Standard Administration and Dosing

The medicine is taken once daily (QD), which establishes a uniform schedule for therapy. The tablets can be taken with or without food and should be consumed with water. To ensure the correct delivery, the film-coated tablets must be swallowed whole and should not be crushed, split, or chewed.

For adults, the typical starting dose is 5 mg once daily. The dose may be increased to the maximum of 10 mg once daily if the initial dose is well tolerated. For pediatric patients (aged 2 years and older), weight-based dosing is used via the oral suspension, maintaining a maximum daily dose of 10 mg.

Procedural Constraints and Adjustments

Strict dose limitations are officially mandated for specific patient groups. The daily dose must not exceed 5 mg in adults diagnosed with severe renal impairment or moderate hepatic impairment (Child-Pugh B). This 5 mg maximum is also required when the medicine is used concurrently with potent CYP3A4 inhibitors.

If a dose is missed, the official instruction is to take it as soon as remembered, but to skip the dose entirely and return to the normal schedule if more than 12 hours have passed since the usual time. The instructions forbid taking two doses in one day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Soline

Evidence for Use in Overactive Bladder (OAB) Syndrome

Research exploring how symptoms change over time in adults with Overactive Bladder (OAB) syndrome primarily involved short-term, randomized, double-blind, placebo-controlled trials (RCTs). These trials are a commonly used design for studying short-term changes and were designed to compare outcomes related to physical discomfort and daily functioning when participants received Soline versus a placebo (an inactive substance).

The main outcomes monitored in these trials were measurements of the daily number of micturitions (urinary frequency), the number of urge incontinence episodes, and the mean volume voided per micturition, which is a functional measure of bladder capacity. Studies conducted during periods of increased symptom activity examined measurements of key symptoms and monitored their evolution over the study period. One of the key limitations in this area of research is that the main placebo-controlled trials were typically limited to an observation period of 12 weeks.

Evidence for Use in Neurogenic Detrusor Overactivity (NDO)

Evidence for the use of Soline in Neurogenic Detrusor Overactivity (NDO), which is a bladder condition often seen in younger patients and marked by neurological-lesion-related detrusor overactivity, differs from the OAB research. Research explored this use primarily in open-label, baseline-controlled Phase 3 studies involving pediatric patients (children and adolescents). These studies observed responses over defined time intervals but typically did not compare the medicine against a placebo. Instead, researchers monitored changes in the patient's own body measures compared to their initial baseline.

Studies examined measurements of Maximum Cystometric Capacity (MCC), a measure of maximum bladder volume, and bladder compliance (elasticity). Because this research relied on baseline-controlled designs rather than randomized, placebo-controlled trials, the certainty remains lower compared to the short-term OAB evidence. Follow-up durations in the randomized studies were limited, although some open-label studies extended the observation period up to 52 weeks.

What Remains Uncertain in the Research Landscape

Research highlights what is known, but evidence also indicates several areas where data are still emerging or remain insufficient. The most significant limitation is that follow-up durations for the randomized, placebo-controlled trials are restricted to only 12 weeks. Long-term effects are not fully established through these controlled studies, and research is ongoing in this area. Data for certain special groups, such as adults with multiple comorbidities, remain insufficient. Research does not fully explain individual variability in patterns of measured change.

Key Studies & References

NIH MedlinePlus Drug Information: Solifenacin Succinate

Frequently Asked Questions (FAQ)

Common questions about Soline (FAQ)

Q: Is Soline considered a 'new' drug, or has it been around for a while?

Soline’s active ingredient was approved by the FDA for use in adults with overactive bladder in 2004. A liquid suspension form for use in pediatric patients with specific neurological conditions received approval later in 2020. Therefore, the original tablet formulation has been available for a significant period.

Q: Is Soline available as a generic medicine?

Yes, the active component of Soline, known as Solifenacin succinate, is officially available as a generic medication.

Q: What is meant by the term 'contraindication' for Soline?

A contraindication is a strict regulatory term for a condition or factor where regulatory documents specify that the medicine should not be used because the potential risk may outweigh the expected benefit under those circumstances. For Soline, official contraindications include severe conditions like uncontrolled narrow-angle glaucoma, toxic megacolon, and known hypersensitivity to the drug.

Q: What color are the Soline pills?

Official descriptions of the tablets specify their color based on strength. The 5 mg tablets are described as light yellow and round, while the 10 mg tablets are described as light pink and round.

Q: Why is the drug description for Soline so complicated?

The technical description, which includes terms like 'muscarinic receptor antagonist' and 'quinuclidine derivative,' is used to precisely define the medicine’s chemical structure and how it works for regulatory and medical purposes. This specific language ensures consistency and accuracy in all official documentation.

Q: Is Soline the same kind of medication as [similar common drug name]?

The official product information classifies Soline’s active component as a muscarinic receptor antagonist, which is a general class of medications used for similar conditions. Research evidence summarized in official documents indicates that its therapeutic effects are comparable to other established medications in this class.

Q: What is the main difference between Soline and other medications in the same class?

The difference between Soline and others in its class is primarily defined by its highly selective mechanism, where it targets the M3 receptors on the bladder muscle. Regulatory documents, however, do not contain specific comparative claims that state Soline is superior to or has a different primary use than other medications in this same group.

Q: Can Soline be used by people over 65 years old?

Soline is authorized for use in adults (age 18 and older). Official warnings advise that older patients may be more sensitive to the medicine's effects, particularly concerning the Central Nervous System. Due to this potential sensitivity, official information indicates that special monitoring may be considered for patients in this age group.

Q: Does Soline build up in your system over time?

The medicine is expected to accumulate in the body until a stable concentration, known as steady state, is reached. This is due to its long elimination half-life, which is officially reported to be between 45 and 68 hours.

Q: What is the half-life of Soline?

The half-life refers to the time it takes for half of the drug to leave the body. Pharmacokinetic data officially states the elimination half-life of Soline is approximately 45 to 68 hours. This value reflects how long it takes for half of the medicine to be cleared from the system.

Q: If I stop taking Soline, do the effects wear off immediately?

No, the effects would not wear off immediately. The active ingredient in Soline has a long elimination half-life, which is officially stated as between 45 and 68 hours. This long duration suggests the effects would wear off gradually.

Q: How does Soline affect driving or operating machinery?

Official warnings describe the need for caution regarding driving or operating heavy machinery. This is due to the potential for side effects such as drowsiness (somnolence) and blurred vision, which may affect a person's ability to perform tasks requiring alertness.

Q: Can taking Soline cause trouble sleeping?

Official side effect data lists Central Nervous System effects, including fatigue and somnolence (drowsiness). While specific instances of insomnia are not frequently listed, official guidance notes that patients should be aware of possible anticholinergic CNS reactions, which may affect the sleep-wake cycle.

Q: Is Soline associated with any warnings about mental health changes?

Official warnings note that Soline is associated with anticholinergic Central Nervous System effects. Serious, though rare, adverse reactions have included confusion and hallucinations, and depression was reported in clinical trial data.

Q: What happens if Soline is taken with alcohol?

Taking Soline with alcohol can lead to intensified side effects. Official guidance indicates that this combination may increase the risk of feeling very drowsy and may also increase the likelihood of dizzy or fainting spells, compounding the Central Nervous System effects of the drug.

Q: Is it true that you can't have grapefruit with Soline?

Grapefruit and grapefruit juice are known to affect how the body processes Soline. Regulatory documents advise that since grapefruit can significantly increase the level of Soline in the bloodstream, official guidance indicates that limiting intake may be recommended, and a lower maximum dose may be considered.

Q: Is there a known interaction between Soline and caffeine?

Yes, official guidance notes that excessive intake of caffeinated beverages may increase urination, which can work against the intended effect of reducing urgency and frequency. This is because caffeine can have effects that oppose Soline’s mechanism.

How should Soline be stored and disposed of?

Soline: Official Storage and Disposal Instructions

Soline (solifenacin succinate) tablets must be stored according to regulatory requirements to ensure product integrity.

Storage Conditions

Condition	Requirement
Temperature	Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F). Do not freeze the medication.
Protection	Keep the tablets in the original package and ensure the container is tightly closed to protect the product from light and moisture.
Child Safety	Keep Soline out of the sight and reach of children.

Disposal of Unused Product

Any unused or expired Soline tablets must be disposed of in accordance with local requirements. Patients should consult a pharmacist or healthcare professional for guidance on disposal, with drug take-back programs being the preferred method. Do not dispose of the medication in household trash or down the toilet unless specifically authorized by official local guidance.

Soline